Torsdag 20 November | 20:18:28 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-10-30 07:30 Kvartalsrapport 2026-Q3
2026-07-10 07:30 Kvartalsrapport 2026-Q2
2026-05-27 N/A Årsstämma
2026-04-30 07:30 Kvartalsrapport 2026-Q1
2026-02-04 07:30 Bokslutskommuniké 2025
2025-10-21 - Extra Bolagsstämma 2026
2025-10-20 - Kvartalsrapport 2025-Q3
2025-07-14 - Split QLINEA 1000:1
2025-07-10 - Kvartalsrapport 2025-Q2
2025-06-26 - Årsstämma
2025-05-23 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2025-04-14 - Kvartalsrapport 2025-Q1
2025-04-03 - Extra Bolagsstämma 2025
2025-02-28 - Bokslutskommuniké 2024
2024-11-05 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-06-28 - Årsstämma
2024-06-12 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2024-05-31 - Kvartalsrapport 2024-Q1
2024-02-27 - Bokslutskommuniké 2023
2023-11-02 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-07-03 - Extra Bolagsstämma 2023
2023-06-13 - Årsstämma
2023-05-24 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2023-05-04 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-11-03 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-25 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2022-05-24 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-26 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2021-05-25 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-16 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2020-05-26 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-18 - Kvartalsrapport 2019-Q2
2019-05-23 - X-dag ordinarie utdelning QLINEA 0.00 SEK
2019-05-22 - Årsstämma
2019-05-03 - Kvartalsrapport 2019-Q1
2019-02-14 - Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Q-Linea är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av instrument och förbrukningsartiklar. Produkterna används huvudsakligen vid behandling av infektionssjukdomar och blodförgiftning, och innefattar diagnostik- och analysverktyg, samt grundläggande provhantering. Tekniken baseras på den så kallade ID- samt AST tekniken. Q-Linea grundades 2008 och har huvudkontor i Uppsala.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-11-20 16:45:00

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA) today announces that it has reached agreement with all relevant unions regarding the company’s new organisation. As part of these changes, Ylva Molin has been appointed to the Executive Management Group (EMG) as Manager of Assay Development effective January 1, 2026. Jonas Melin, Director of Product Development, will step down from the EMG and will remain employed with Q-linea as Senior Technical Advisor, ensuring continuity across key development programs. The company also announces the planned departure of Christer Samuelsson, Chief Financial Officer.

In line with the cost savings program previously announced (Oct 22, 2025), Q-linea is implementing a streamlined organisation aimed at strengthening its commercial focus and improving operating efficiency. As a result, headcount will be reduced by 16 employees as of January 1, 2026 compared with the reported level of 83 ending Q3 2025. These reductions are limited to Sweden; operations in the US and Italy remain unaffected and continue to support ongoing customer needs.

Ylva Molin, currently Manager of Assay Development, joins the EMG with 13 years of experience at Q-linea, having led several critical development projects and teams.

CFO Christer Samuelsson will leave the company following the onboarding and orderly transition to a new CFO, expected during the first half of 2026.

Jonas Melin, who has led the Research and Development team for nearly 10 years, will transition from his EMG role on January 1, 2026, and continue to provide core expertise in a senior advisory capacity.

“These changes reflect the continued evolution of the Q-linea team as we accelerate our commercial strategy and focus our development portfolio”, says Q-linea CEO Stuart Gander. “I would like to thank both Jonas, who has been a pivotal leader of our scientific and technological progress, and Christer, who has successfully guided the company through a critical period of financial development. Both have elected to rebalance time for other projects. We are pleased to welcome Ylva to the senior leadership team – her deep experience with ASTar application development will be highly valuable as we move into the next phase of our journey.”